Title
Comparative effectiveness of antiviral therapies in chronic hepatitis B and C management
Authors
Ashis Tiwari1, Praveen Kumar Tagore1, Sukh Dayal Kumhar1 & Abha Bardiya2,*
Affiliation
1Department of General Medicine, Government Medical College, Datia, Madhya Pradesh, India; 2Department of Anaesthesiology, Shyam Shah Medical College, Rewa, Madhya Pradesh, India; *Corresponding author
Ashis Tiwari - E-mail: ashishtiwari.gwldr@gmail.com;
Phone: +91 6263218871
Praveen Kumar Tagore - E-mail: tagore.praveen@gmail.com; Phone: +91
9911894191
Sukh Dayal Kumhar - E-mail:
dr.sd.prajapati@gmail.com; Phone: +91 9131104498
Abha Bardiya - E-mail: bardiya.abha@gmail.com; Phone: +91 9691687723
Article Type
Research Article
Date
Received March 1, 2026; Revised March 31, 2026; Accepted March 31, 2026, Published March 31, 2026
Abstract
Chronic hepatitis B and C infections affect over 350 million people worldwide, leading to progressive liver disease that demands effective antiviral therapy. Hence, this study compares four antiviral regimens across 480 patients (4 groups of 120 each): tenofovir or entecavir for HBV and sofosbuvir-based or glecaprevir/pibrentasvir combinations for HCV over 48 weeks. Glecaprevir/pibrentasvir achieved superior HCV suppression (96.7% SVR versus 94.2% sofosbuvir-based, p=0.032), while HBV showed 100% tenofovir versus 87.8% entecavir suppression (p=0.421). Both drug classes demonstrated high efficacy in halting viral replication and minimizing progression to chronic liver damage. These results advance therapeutic knowledge by identifying glecaprevir/pibrentasvir as a marginally superior HCV regimen and reinforcing evidence-based antiviral selection for durable viral suppression.
Keywords
Chronic hepatitis B (HBV), chronic hepatitis C (HCV), antiviral therapy, direct-acting antivirals, nucleoside analogues, sustained virologic response, treatment effectiveness
Citation
Tiwari et al. Bioinformation 22(3): 1367-1373 (2026)
Edited by
Vini Mehta
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
